18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)

This publication has 19 references indexed in Scilit:

• Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors
  Journal of Clinical Oncology, 2002
• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
  New England Journal of Medicine, 2002
• Whole-body FDG-PET imaging in the management of patients with cancer
  Seminars in Nuclear Medicine, 2002
• Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
  Blood, 2001
• Gleevec (STI571) Influences Metabolic Enzyme Activities and Glucose Carbon Flow toward Nucleic Acid and Fatty Acid Synthesis in Myeloid Tumor Cells
  Journal of Biological Chemistry, 2001
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
  The Lancet, 2001
• Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
  New England Journal of Medicine, 2001
• Clinical role of positron emission tomography in oncology
  The Lancet Oncology, 2001
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
  European Journal Of Cancer, 1999